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 Abstract 
 
Whist the host immune response following primary human cytomegalovirus (HCMV) 
infection is generally effective at stopping virus replication and dissemination, virus is never 
cleared by the host and like all herpesviruses, persists for life. At least in part, this 
persistence is known to be facilitated by the ability of HCMV to establish latency in myeloid 
cells in which infection is essentially silent with, importantly, a total lack of new virus 
production. 
However, although the viral transcription programme during latency is much suppressed, a 
number of viral genes are expressed during latent infection at the protein level and many of 
these have been shown to have profound effects on the latent cell and its environment. 
Intriguingly, many of these latency-associated genes are also expressed during lytic 
infection. Therefore, why the same potent host immune-responses generated during lytic 
infection to these viral gene products are not recognised during latency, thereby allowing 
clearance of latently infected cells, is far from clear.                                                     
Reactivation from latency is also a major cause of HCMV-mediated disease, particularly in 
the immune compromised and immune naïve, and is also likely to be a major source of virus 
in chronic subclinical HCMV infection which has been suggested to be associated with long-
term diseases such as atherosclerosis and some neoplasias. Consequently, understanding 
latency and why latently infected cells appear to be immunoprivileged is crucial for an 
understanding of the pathogenesis of HCMV and may help to design strategies to eliminate 
latent virus reservoirs, at least in certain clinical settings. 
 
  
Introduction 
Human cytomegalovirus (HCMV) is a paradigm for viral immune evasion strategies yet, 
paradoxically, primary infection of immunocompetent individuals rarely causes serious 
disease and such primary infections are normally quickly resolved. In contrast, infection of 
individuals whose immune systems are compromised (such as HIV/AIDS patients and 
transplant patients) or immature (such as the foetus in utero) often leads to wide spread viral 
replication and dissemination to multiple organs and this can often be life threatening (1) (2). 
Despite the success of the primary immune response in resolving primary infection, HCMV is 
never cleared. In part, this is due to the ability of the virus to establish a latent infection from 
which periodic viral reactivation is thought to facilitate lifelong viral persistence. 
Whilst our understanding of the mechanisms by which HCMV evades host immune 
surveillance during lytic infection is substantial (3-7), far less is known about how this may be 
achieved during latent infection; yet it is likely that this may also be of real importance for the 
maintenance of viral latency. Historically, a long held view was that the relatively silent 
nature of a latent infection, with respect to viral gene expression, was, in itself, a mechanism 
of immune-avoidance. However, over the last few years, our understanding of  latency-
associated changes in the cell and cellular environment has increased and it is becoming  
clear that latent virus is far from quiescent; latent infection has profound effects on the cell 
and manipulates numerous cellular functions to optimise cell survival and latent genome 
carriage (8-10) and this results from latency-associated expression of a number of viral 
genes which are, more often than not, also expressed during lytic infection. Consequently, 
why these viral gene products are not targeted by the same potent host immune-responses 
generated during lytic infection to clear latently infected cells is a key question. This review 
examines the rationale and strategies for immune evasion by HCMV during latent infection 
and discusses how this knowledge could lead to potential immune interventions to target 
latent HCMV in patient groups where this might be particularly desirable. 
Primary infection and the immune response to virus in lytic phase 
Primary HCMV infection induces robust innate and adaptive anti-viral immune responses  
and in most cases does not cause serious disease (3, 11). For instance, primary HCMV 
infection results in a potent NK cell response (7) as well as the generation of humoral 
immunity, which includes neutralizing antibodies, which are specific for a number of viral 
proteins (12, 13). In addition to antibody responses, primary HCMV infection also results in 
the generation of  both CD4+ and CD8+ T cells specific for a very broad range of viral 
proteins (3, 11, 14) at very high frequencies (Figure 1). It is recognized that primary infection 
of immunosuppressed individuals,  or the immunonaive foetus in utero, leads to extensive 
viral replication in numerous cell types and, ultimately, end organ disease which can result in 
serious morbidity and in some cases mortality (15-18). Also, whilst infection of newborns 
(which are also considered immunologically immature) does not cause such serious 
morbidity as infection in utero, viral replication in the young may take a much  longer time to 
be brought under control as evidenced by prolonged shedding of the virus in urine and saliva 
(19).  
Taken together, these data provide reasonable evidence that the immune response mounted 
during primary infection is effective at limiting lytic viral replication and preventing serious 
disease. However, despite this, latency is always established and virus is never cleared 
(Figure 2). In some ways this is surprising as it is very clear that HCMV encodes numerous 
and sophisticated immune evasion mechanisms, so much so that it is has become 
somewhat of a paradigm for how a human pathogen can avoid host immune responses (3). 
For instance, during lytic infection, specific genes encoded by HCMV can directly modulate 
innate immune responses such as the interferon responses (5) and NK cell recognition (7). 
The virus also encodes an immunosuppressive IL-10 homologue (20, 21), IL-10 is a 
powerful inhibitor of Th1 cytokines (such as  IFN γ and IL-2) and also inhibits  inflammatory 
cytokine production from monocytes and macrophages which results in a decrease  in 
surface MHC Class II expression and a reduction of  presentation of antigen to CD4+ T cells 
(22). In addition, the virus also encodes  proteins that act as receptors for host inflammatory 
cytokines, thereby reducing  localized cytokine effectiveness by acting as cytokine sinks (6). 
Similarly, a number of HCMV encoded genes known to be expressed during lytic infection 
can interfere with both MHC Class I and II restricted antigen processing and presentation, 
thereby robustly inhibiting  CD4+  and CD8+ T cell recognition (4, 23) as well as co-
stimulatory T cell signalling (24) (Figure 3). On one hand then, HCMV expresses multiple 
immunevasins which are known to work potently in vitro but, even in the face of these, host 
immune response are still able to resolve primary HCMV infection. One view consistent with 
many of these observations is that these host anti-viral responses, which are able to resolve 
primary infection, are not able to target latent virus infection efficiently and this results in viral 
persistence, at least in part, involving periodic viral reactivation from a more immunologically 
privileged latent reservoir. 
 
Although the immune evasion mechanisms employed by HCMV in vitro are very well 
documented, the effectiveness of these during primary infection in vivo is not absolutely 
clear and perhaps may be better seen as viral functions which allow the pathogen to initially 
overcome host immune responses and thus create a window of opportunity for the virus to 
replicate efficiently and disseminate to cell types where latency can be established. Such a 
strategy could be conceived to be optimal for a life-long persistent pathogen as unchecked 
viral replication, leading to host mortality, would clearly be a dead end strategy for any virus. 
However, the establishment of quiescence would also, in itself, be a biological dead end for 
any virus unless it was able to reactivate from this quiescent state and re-establish lytic 
infection in order to exit the host and establish an infection in naïve individuals. Similarly, a 
fitting time for a comprehensive set of immunevasion functions to be employed by the virus 
would be during reactivation from latency; these would again create a window of opportunity 
for the virus to re-establish the production of new virions in the face of an existing and 
primed anti-viral immune response. In the rest of this review we will discuss viral gene 
expression during latency and how this latency-associated gene expression may aid immune 
evasion to allow maintenance of the latent reservoir.  
 
 
 
Establishment of latency and the molecular biology of the latently infected cell 
One important site in which HCMV is known to establish latency is in cells of the myeloid 
lineage. Latent viral genomes can be detected in peripheral monocytes (25) and also traced 
back to their CD34+ progenitors in the bone marrow (26) (27). Intriguingly, although CD34+ 
bone marrow progenitor cells are also the source of cells of the lymphoid lineage, there is no 
evidence of viral genome carriage in peripheral blood B or T cells  (25). This may in part be 
explained by recent evidence suggesting that latent infection itself may result in some partial 
commitment of CD34+ progenitors to the myeloid lineage (28).  
Consistent with cells of the myeloid lineage being sites of latent infection, analyses of the 
viral transcription programme in these cells generally shows a suppression of viral lytic gene 
expression (2, 29-32) but concomitant  expression of known latency-associated viral genes 
(31, 33-37). Importantly, these cells do not produce infectious virions; an essential 
characteristic of latent infection. In latent myeloid cells in vivo, this suppression of the lytic 
transcription programme appears to involve repression of the viral major immediate early 
promoter (MIEP), which would normally drive lytic cycle, through post-translational 
modification of histones around the MIEP resulting in the presence of well characterised  
repressive chromatin marks (reviewed in (2)).  Also, importantly, this latent transcription 
programme can be reactivated to lytic cycle by differentiation of latent CD34+ cells or 
monocytes to macrophages or dendritic cells (DCs) resulting  in expression of the 
established lytic temporal cascade of viral gene expression, leading to viral DNA replication 
and de novo virus production (36, 38-40). Crucially, this reactivation of the lytic cascade of 
gene expression is initiated by the expression of the major immediate early proteins (IE72 
and IE86); IE gene expression, thus, acts as a master regulator to initiate lytic cycle ((41-44) 
and Figure 4)). 
It is worth noting that many of these analyses of naturally latently infected cells can also be, 
in general, recapitulated in experimental models of latency in vitro. CD34+ progenitors, 
monocytes and granulocyte-macrophage progenitors (GMPs), as well as some established 
myeloid cell lines, can be infected in culture allowing the maintenance of latent viral 
genomes which can then be reactivated by differentiation signals  (21, 30, 35-37, 45-47). 
Although it is clear that some experimental models using established cell lines do not appear 
to fully recapitulate all aspects of control of latency and reactivation observed in primary 
myeloid cells  (48). 
A totally quiescent viral genome during latent infection would clearly be the ideal way to 
avoid immune surveillance - if viral proteins are not expressed at all there would be no 
processing and presentation of viral antigens to specific T cells and, thus, latently infected 
cells would be ignored by the host immune response. However, recent work has shown that 
the viral gene expression is far from quiescent during latent infection and that expression of 
a number of viral transcripts, encoding viral proteins, routinely occurs (10, 47). 
There is now much published data detailing expression of specific viral genes during natural 
or experimental latent infection in CD34+ cells or their myeloid derivatives. Transcripts 
expressed during natural latency are known to include RNAs from the major IE region 
(UL122-123 CLTs) (31) as well as UL81-82ast (LUNA) (34), UL138 (35), UL111a (33), 
UL144 (28) and US28 (49)  but, more recently, additional latency-associated viral transcripts 
have also been identified (29). The detailed functions of these viral genes, where known, are 
beyond the scope of this article but have been described in recent reviews (10, 47). 
However, the potential immune evasion functions of UL111a and US28 will be discussed 
later. 
HCMV, as with many other herpes viruses, have been shown to encode a wealth of 
microRNAs (miRNAs) with the potential to orchestrate both cell and viral gene regulation 
(50). During lytic infection HCMV expresses approximately 24 miRNAs derived from 13 pre-
miRNAs which have been shown to target both viral and cellular RNAs. Viral targets include 
IE72 as well as a number of viral genes involved in DNA synthesis and it has been 
suggested that these targets might play some role in latency establishment and reactivation 
(51-53) although, as yet, there is no direct evidence for this. Cellular targets of HCMV-
encoded miRNAs include gene products with functions relating to control of cell cycle, 
secretory cellular pathways and, of particular interest, immune evasion (54-56). Most of 
these targets have been analysed during lytic infection and, again, are outside the scope of 
this article but have recently been reviewed (50). However, we will discuss the role of viral 
miRNAs in targeting gene expression associated with immune evasion mechanisms below. 
Whilst much is known about the interdiction in cellular and viral gene expression by viral 
miRNAs during lytic infection, there is a dearth of information regarding the expression of 
viral miRNAs during latent infection; yet it could be argued this might be the most opportune 
scenario for viral miRNA functions. For instance, it could allow an orchestrated manipulation 
of cellular gene expression without the need to express viral proteins which, otherwise, could 
be targeted by host immune mechanisms. Reports using a quiescent THP1 model infected 
with either Towne (57) or Toledo (58) isolates of HCMV have identified a number of 
expressed viral miRNAs, although their functions during quiescence was not addressed and, 
at least for Towne, it is unclear how this might inform us as Towne does not usually 
efficiently infect myeloid cells (59) and is depleted of some important viral coding regions 
(60). In our attempts to address this, we have used RT-qPCR to detect viral miRNAs 
expression in primary CD34+ myeloid progenitors and CD14+ monocytes experimentally 
latently infected with a clinical isolate of HCMV. These studies have shown that a number of 
viral miRNAs are indeed expressed during latent infection but, whilst their targets and 
functions during latency are unclear, early evidence suggests that some may be involved in 
manipulating myeloid differentiation (IHW Kobe, Japan 2014 - Betty Lau, unpublished 
observations).  
The view that latent infection has profound effects on the latently infected cells has come 
from recent work analysing experimentally latent primary CD34+ cells. These studies have 
shown that latent infection results in the modulation of the cell secretome (61), in part 
mediated by latency-associated modulation of the cell miRNAome (62). In more detail, 
during latency the cellular miRNA, has-miR-92a, is downregulated and leads to an 
upregulation of the transcription factor GATA2 and subsequent increased expression of 
cellular IL-10 (cIL-10) which is of particular interest in the context of immune evasion 
strategies and latency (62). Interestingly, quiescent infection of THP1 cells has also been 
shown to alter cellular miRNA expression (58). 
Thus, it is clear that latent infection is far from a passive interaction between the virus and 
the cell; latent infection results directly in numerous changes in the cell phenotype which 
likely optimise the cell for latent carriage and reactivation. It is also likely that expression of 
latency-associated viral miRNAs and modulation of the cellular miRNAome plays a major 
part in orchestrating such changes in cellular gene expression and this strategy circumvents 
expression of viral functions which would be normally be surveilled by host immune 
responses. However, latent infection also results in expression of a number of virus encoded 
proteins which would be predicted to lead to e.g. T cell recognition unless latent functions 
also include viral strategies to mediate immune evasion.  
 
Immune evasion strategies during latent infection 
(i) virally encoded miRNAs and proteins 
Our understanding of the functions of specific viral genes during lytic infection may inform us 
of their potential functions during latency, if their expression is also latency-associated.   
Three viral miRNAs have been shown to target components of the immune system during 
lytic infection. miR-UL112.1 targets MICB a cellular stress (infection) induced ligand which 
usually functions by binding the homodimeric NK cell activating receptor NKG2D (54); miR-
US4.1 downregulates ERAP-1 which is an amino-peptidase which trims peptides for 
presentation by MHC Class I and reduced ERAP-1 expression decreasing HCMV specific 
CD8+ CTL recognition of HCMV infected cells (55); miR-UL148D targets the chemokine 
CCL5 (RANTES) which is a T cell chemoattractant (56). 
Interestingly, miR-UL112.1 and miR-US4.1 have been detected in quiescently infected THP1 
cells (57, 58) and we have also detected all three viral mRNAs in experimentally latent 
CD34+ cells and CD14+ monocytes (IHW Gdansk, Poland 2012 and CMV meeting San 
Francisco, USA 2013 Lau et al unpublished). Consequently, there is a good likelihood that 
these viral miRNAs may also have some role during latency to help mediate avoidance of 
the host immune response. However, direct confirmation of this during latency awaits more 
detailed investigation. 
Three HCMV proteins, US28, UL111A, and UL144 also known to be expressed in latently 
infected cells, have known immune evasion functions, at least during lytic infection, which 
could be equally well employed during latent infection. US28 is a G-protein coupled receptor 
that can bind both CC (eg CCL5, MCP-1, MCP-3, MIP1-α, and MIP1-β) and Cx3C (eg 
fractalkine) chemokines. The ability of US28 to bind multiple cytokines and cause their 
internalization, allows it to act as a chemokine sink, reducing the local concentration of these 
inflammatory and chemotactic cytokines during lytic infection in vitro, although transcripts for 
US28 can be detected in latency, the level of protein expression and thus its potential to act 
as a cytokine sink has not yet been investigated (63). Similarly, a latency-associated splice 
product of UL111A encodes a viral IL-10 homologue (LAvIL-10)  and acts to downregulate 
MHC Class II expression on experimentally latently infected myeloid cells and this modulates 
CD4+ T cell recognition (20, 64, 65). UL144 has sequence similarity with members of the 
tumour necrosis factor receptor superfamily (TNFRSF) (66-68) as well as the herpes simplex 
virus entry mediator (HVEM). However, UL144 is unlikely to act as a decoy TNF receptor 
and there is no evidence that UL144 binds TNF (69). UL144 has two putative immune 
evasion functions; the ecto-domian has been shown to interact with B and T lymphocyte 
attenuator (BTLA) and inhibits T cell proliferation in vitro (70)  and the intracellular domain 
signals via NFkB, TRAF6 and TRIM23 to induce the chemokine CCL22 which acts as a TH2 
chemoattractant possibly subverting the TH1 immune response (69, 71, 72).  
 
(ii) Manipulation of the cellular microenvironment by changes in the cell secretome  
HCMV lytic infection is also known to induce profound alterations in levels of secreted 
cellular proteins (secretome) and this includes a number of chemokines and cytokines with 
immune functions (73, 74). However, until recently, little was known about latency-
associated changes in the cell secretome. The possibility that viral manipulation of secreted 
cellular proteins would likely be an effective mechanism to modify the microenvironment 
around latently infected cells to help maintain life-long carriage of latent virus in the face of 
constant immune surveillance has been investigated by us and others.  
Such studies showed that experimental latent infection of granulocyte macrophage 
progenitor cells (GMPs) attracted CD14+ monocytes and that this was mediated by an 
increase in CCL2 (MCP-1) expression by the latently infected GMP (21). Subsequently, a 
comprehensive analysis of the secretome of experimentally latently infected CD34+ 
progenitor cells identified changes in numerous secreted cellular proteins which are known 
to be involved in both the regulation of the immune response and chemo-attraction (61). In 
these studies, a latency-associated increase in the chemokine CCL8, perhaps 
counterintuitively, resulted in the recruitment of CD4+ T cells to latently infected cells. 
However, these supernatants also had substantial increases in levels of the immune 
suppressive cytokines cIL-10 and TGFβ which were sufficient to inhibit anti-viral IFNγ and 
TNFα cytokine secretion as well as cytotoxic effector functions of HCMV-specific Th1 CD4+ 
T cells. An additional interesting aspect was that uninfected bystander CD34+ cells were 
also induced to express TGFβ and cIL-10 by the secretome from latently infected cells. In 
essence, the microenvironment around latently infected CD34+ cells was heavily 
immunosuppressive (Figure 5). Recent evidence has also shown that experimentally latent 
CD14+ monocytes modulate the cellular responses to innate stimuli such as type I and II 
interferon’s by disrupting signaling via STAT1 (75). 
 
(iii) Latency-associated proteins and T cells responses 
Viral proteins expressed during latency appear  to have important roles in maintaining 
latency and assisting in viral immune evasion. However, why these viral proteins don't act as 
target antigens to allow host T cells to detect and kill latently infected cells is an important 
question. Could it be that T cells specific for these viral proteins are, for some reason, never 
induced following HCMV infection? 
Recently, examination of T cell responses to four viral proteins expressed during latency 
(LUNA and UL138, US28 and LAvIL-10) have shown  that this is not the case - T cell 
responses specific for all four proteins are, indeed, detectable in healthy HCMV positive 
donors (76).  Intriguingly, all responses identified appeared to be mediated by CD4+ T cells - 
no CD8+ T cell responses were detected and this is broadly in agreement with a separate 
analysis of LUNA and UL138-specific T cell responses where no CD8+ T cell responses to 
LUNA and only a single peptide from UL138 presented via a particular class I allele (HLA-
B35) were detected (77). It is not clear why this bias towards CD4+ T cell responses to 
proteins expressed during latency occurs, although it has also been observed in the T cell 
response to HCMV encoded glycoprotein B (78). It would be informative to examine the  
primary responses to latency-associated proteins such as UL138 and LUNA and follow them  
longitudinally  after primary infection with respect to  selection of T cells into memory. This 
would help determine if CD8+ T cells are initially generated but are then lost or if they are 
never generated in the first place. UL138, but not LUNA, specific CD4+ T cells were also 
shown to be able to mediate MHC class II restricted cytotoxicity and, importantly, they also 
recognize latently infected autologous monocytes. Importantly, a proportion of the UL138, 
LUNA ,US28 and LAcmvIL-10 specific CD4+ T cells also secreted the immunomodulatory 
cytokines cIL-10 and TGF-β (61) and this may help explain why T cell recognition of these 
latently expressed proteins, in vivo, does not result in their elimination;  the CD4+ T cell 
populations which recognise these latent antigens are predominantly regulatory and, in 
combination with the suppressive microenvironment produced by the latently infected cell, 
appears to limit the function of anti-viral IFNγ/TNFα and cytotoxic Th1 CD4+ T cells (Figure 
5). A similar mechanism has been described for the latent EBV antigen LMP1 which also 
gave rise to cIL10 producing regulatory cells (79). Similarly, in MCMV infection, IL10 
producing CD4+ T cells have been isolated from salivary glands and, in IL-10 KO mice or 
following IL-10R blockage the latent MCMV load is reduced. This is consistent with the view 
that cytomegalovirus uses regulator T cell to prevent latently infected cells from being 
recognised by the immune system (80, 81). 
 
 
Is immune targeting of latently infected cells possible and in what patient groups 
would it be most effective?  
It is now clear that reactivation of virus from latent reservoirs is a major cause of the HCMV-
mediated disease observed in the transplant setting where patients are immunosuppressed. 
Increasingly, it is also recognised that HCMV seronegative women are not the only group 
that are at risk during pregnancy - reactivation in HCMV seropositive carriers can also be a 
source of virus transmission to the foetus during pregnancy (82). Similarly, there are data 
which suggest that subclinical HCMV infection may be associated with long-term diseases 
such as atherosclerosis, chronic graft rejection and neoplasias – where, clearly, reactivation 
is likely to be a major source of infectious virus (83).   
(i) The transplant setting 
Following solid organ transplantation (e.g. liver, kidney, heart or lung), transfer of latent 
HCMV in the graft from a seropositive donor (D+) to a seronegative recipient (R-) frequently 
leads to serious HCMV disease in these patients who are also receiving immunosuppressive 
treatments (16). Similarly, although not associated with the same risk, D+/R+ or D-/R+ 
transplant patients also suffer from intermediate risk of HCMV disease often from virus 
reactivation. 
Bone marrow transplantation (BMT) and peripheral hematopoietic stem cell transplantation 
(HSCT), often as part of the therapy for haematological malignancies, has steadily grown 
over time and, as with solid organ transplant patients, reactivation of latent HCMV often 
leads to serious morbidity and mortality in these immunosuppressed patients. Importantly, in 
allogeneic HSCT, the serostatus of the graft donor determines whether latent virus could be 
transferred to the recipient, as well as determing if HCMV antigen specific T cells are 
transferred as well. Therefore, the greatest risk of HCMV disease in HSCT occurs in a D-/R+ 
transplantation scenario, because the graft from the seronegative donor does not contain 
antigen-experienced HCMV-specific T cells. In this situation, reactivation of the recipient's 
latent virus goes unchecked due to immune ablation of the recipient as well as  
immunosuppressive treatment, post-transplant, to prevent GvHD. It might be expected that 
the immune ablation regime, itself, should remove all myeloid lineage cells  carrying latent 
virus and, as a consequence, clear latent viral carriage. However, clinical evidence shows 
that this group of patients still undergo viral reactivation which, in the absence of an immune 
response, is able to replicate and disseminate. Therefore, it is likely that the latent reservoir 
is not fully destroyed by the ablation regime. In contrast, studies consistently report that 
almost all D+/R+ transplantations show early and sustained reconstitution of pp65 tetramer 
positive T cells (84-87).  
 
(ii) Reactivation during  pregnancy 
HCMV infection in utero is estimated at between 0.4-0.7% of live births in the USA and a 
similar rate in European countries (18). Whilst the greatest risk for HCMV disease of the 
foetus is accepted to be primary infection of naïve mothers, the risk of maternal-to-fetal 
transmission is substantially lower in seropositive women (88) suggesting that pre-existing 
immunity is beneficial. The incidence of congenital HCMV infection does, however, correlate 
with HCMV seroprevelance (82, 88-90). Consequently, non-primary infections  caused by 
either  re-infection of, or reactivation in,  HCMV seropositive mothers are also likely to be a 
cause of congenital infection despite preformed HCMV specific maternal antibodies. 
Although the relative contribution of virus reactivation or re-infection to congenital infections 
is not clear  (91), prevention of infection in either scenario would be beneficial. Whilst this 
could be achieved through education of pregnant mothers (e.g. in hygiene measures), any 
potential therapy to reduce the latent viral reservoir during pregnancy could also reduce the 
risk of congenital infection from virus reactivation. 
Cearly, then, there are a number of clinical settings in which the ability to therapeutically 
target latently infected cells could have far reaching implications.  Drug based interventions 
that target specific aspects of the latent virus life cycle are an attractive possibility and the 
recent discovery that viral UL138, which is expressed during latent infection, is able to inhibit 
a cellular drug transporter has lead to an exciting proof of principal that it is possible to 
chemotherapeutically target latently infected cells (92). 
Our increasing understanding of changes in latently infected cells, and the likelihood that 
HCMV also needs to employ specific latency-associated functions to proactively suppress 
host immunesurveillance during latency, argues that latent infection might also be targeted 
by manipulating or perturbing these specific mechanisms employed by HCMV to prevent 
immune detection by the  host during latent carriage.  
Which patient groups would lend themselves most easily this type of immunotherapeutic 
approach? In the case of HSCT, there would be an opportunity to manipulate the CD34+ 
cells in vitro prior to transplantation to remove cells carrying latent virus. This would be 
particularly attractive in a D+/R- transplant scenario. However, this approach might be more 
difficult in the case of a solid organ transplant where e.g. efficient perfusion might be 
problematic. Regardless, both of these could be carried out on donor material prior to 
transplant. Clearly, in the case of reduction of the latent load during pregnancy to limit 
reactivation, any therapeutic would need to be delivered, as would strategies to reduce 
recipient latent load prior to transplant.  
 
Removal of latent cells from the HSCT graft 
Could the T cells specific for viral proteins expressed by latently infected cells be harnessed 
to target and reduce the latent virus load? Prior to HSCT, the CD34+ graft is routinely 
manipulated to remove T cells in order to minimise graft versus host disease (GvHD). In the 
scenario of an HCMV seropositive donor and an HCMV seronegative (D+/R-), when the graft 
itself carries latent virus, it could be feasible, at the same time, to eliminate or drastically 
reduce the latent viral load prior to transplantation to reduce the level of reactivatable virus. 
 On the basis that anti-viral CD4+ (Th1) T cells are generated to viral proteins expressed by 
latently infected cells; that the block to the effective functioning of these cells appears to be 
the presence of antigen specific immune suppressive CIL-10/TGFβ secreting T cells (76) and 
that latently infected cells also produce an immunosuppressive cytokine milieu (61), we 
speculate that antibody neutralization of CIL-10/TGFβ in combination with the depletion of 
regulatory T cells might allow Th1 type CD4+ latent antigen specific T cells to recognize and 
kill latently infected CD34+ cells in the graft (Figure 6). T cell depletion of the graft to reduce 
GVHD would then ensue, resulting in a CD34+ cell population depleted of latently infected 
cells which would limit the amount of virus capable of reactivating from the graft after 
transplant. In the D-R+ HSCT setting, this approach would not be helpful as the graft does 
not contain latent virus and, as such, a different approach would be required. For instance, 
the induction of some aspect of immunogenic  lytic gene expression, in the absence of viral 
immune evasins,  in the latent reservoir of the recipient could be one approach - and this is 
discussed in the next section. For obvious reasons, harnessing the latent antigen specific T 
cells to kill latently infected CD34+ cells in this way would likely not be feasible for a solid 
organ graft. Similarly, it is difficult to how this approach could be employed to target the 
latent reservoir during pregnancy.   
Induction of immunogenic lytic genes in the absence of immunomodulation 
As discussed earlier in this review, specific T cell responses to viral immediate early proteins 
are mounted by most HCMV seropositive individuals and are high frequency. In healthy 
HCMV carriers, these T cell responses routinely comprise both CD4+ and CD8+ T cells 
which both have antiviral and cytotoxic activity. While these T cells are clearly effective at 
controlling dissemination of viral infection following reactivation, they are of little use in 
detecting latently infected cells which do not express IE proteins; not only is the MIEP 
heavily suppressed in these cells to minimise IE RNA transcription but our own unpublished 
data suggests that expression of the viral UL112-1 miRNA functions to minimise translation 
of any IE RNA which escapes MIEP transcriptional repression (IHW 2013 Grand Rapids, 
USA Lau et al unpublished observations).  If cells carrying latent HCMV could be induced to 
transiently express viral immediate early proteins, in the absence of full virus reactivation, 
this may allow the endogenous antiviral T cell response to recognize latently infected cells 
expressing IE antigen in this untimely fashion and kill them. 
It has been recognized for some time that inhibition of histone deacetylase activity in a non-
permissive cell type that is carrying HCMV genome leads to IE promoter activity, but 
importantly not full virus reactivation (93). Consequently, this might be used as an approach 
to render cytomegalovirus latently infected cells transiently visible to the host immune 
response (Figure 6). In initial pilot experiments we have been able to induce IE gene 
expression using HDAC inhibitors in latently infected monocytes (Poole et al unpublished 
observations) and these cells, transiently expressing IE1 protein are recognised by IE 
specific T cells on the basis of IFNγ secretion. Importantly, there are already a number of 
HDAC inhibitors which are licensed for use in patients (94). Consequently, we think it 
feasible that treatment of patients with such agents could result in transient reactivation of IE 
gene expression in vivo allowing latently infected cells to be identified and eliminated by 
existing IE-specific CTLs. Clearly, such novel immunotherapies would be applicable to a 
much wider group of patients and require no ex vivo manipulations of latent cell populations. 
It is worth noting that similar approaches are currently being tested in cell populations 
latently infected with HIV-1 to promote "reawakening" of latent HIV gene expression to allow 
these cells to be recognized and eliminated by HIV specific T cells (95-97). 
There is a very clear rational behind reducing the latent load within an individual person  to 
limit viral reactivation, however this clearly needs to be balanced by the risks that such an 
intervention may carry with it. In the case of particular clinical settings, such as 
immunosuppression in transplantation, we would suggest that this balance is in favour of 
using chemotherapeutic and/or immunological techniques to reduce the latent reservoir. In 
other settings, such as pregnancy, while the benefits might be desirable much greater 
caution with regard to the particular intervention would need to be exercised.  
We believe that continued detailed analyses of viral gene expression during HCMV latency 
is important for a complete understanding of how latent virus manipulates the cellular 
environment in order to maintain latency while evading immune recognition. This can only 
help in the design of effective and safe novel strategies to target and clear latent virus that 
could be applied in certain clinical settings. 
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Figure Legends 
Figure 1 
Following primary infection, HCMV replicates and disseminates during which time  the host 
generates an effective immune response which includes natural killer cells, neutralizing 
antibodies and a high frequency of CD4+ and CD8+ T cells. This eventually controls viral 
replication and resolves the primary infection.  
 
Figure 2 
HCMV replicates and disseminates leading to infection of myeloid progenitors and the 
establishment of latent infection in e,g, CD34+ bone marrow progenitor cells. Reactivation of 
virus from these sites followed by new virus replication and productive replication induces 
secondary immune responses. 
 
Figure 3 
During lytic infection, HCMV expresses numerous viral proteins which mediate immune 
evasion. These include viral genes which  interfere with  host interferon responses, natural 
killer cell recognition (eg UL16, 18, 40, 141,142,US18, US20) as well as CD4+ and CD8+ T 
cell recognition  by preventing MHC Class I and II antigen processing and presentation (eg 
US2-US11). Other viral genes, such as the viral IL-10 homologue (UL111a) as well as viral 
proteins that act as receptor sinks for host inflammatory cytokines (US28), aid in general 
suppression of the host immune responses. 
  
Figure 4 
HCMV can establish latency in CD34+ myeloid progenitor cells and is carried down the 
myeloid lineage. In latently infected CD34+ cells and CD14+ monocytes there is a targeted 
suppression of lytic viral gene expression and generally undetectable levels of major IE 
proteins. However, expression of a number of latency-associated genes is  detectable. 
These include transcripts from the major IE region (UL122-123 CLTs), UL81-82ast (LUNA), 
UL138, UL111a, UL144 and US28 although, more recently, other RNAs have been identified 
(28). Differentiation of these cells to macrophages and mature dendritic cells (mDCs) causes 
the de-repression of the MIEP and allows initiation of the lytic transcription programme which 
involves a temporal cascade of viral gene transcription and translation (consisting of 
immediate early, early and late gene products),  allowing viral DNA replication and 
reactivation of de novo virus production. 
 
Figure 5 
Latently infected CD34+ cells produce a secretome high in immunosuppressive cytokines 
such as cellular IL-10 (cIL-10) and TGFβ which act to inhibit anti-viral CD4+ cytokine and 
cytotoxicity (Th1) cell effector function. Uninfected bystander CD34+ cells are also induced 
to secrete cellular IL-10 (cIL-10) and TGFβ further enhancing the immunosuppressive 
microenvironment.  Antigen specific CD4+ regulatory T cells also recognize latent viral 
proteins and secrete their own cIL-10 and TGFβ which also generates an 
immunosuppressive microenvironment, so helping to prevent clearance of latently infected 
cells. 
 
Figure 6 
Neutralization of the immunosuppressive cytokines cIL-10 and TGFβ and/or depletion of 
regulatory T cells could allow latent viral proteins to be recognized by anti-viral CD4+ (Th1) 
effector cells.  
Treatment of latently infected cells with HDAC inhibitors could also allow transient 
expression of viral IE proteins which, after processing and presentation by Class I MHC, 
would be predicted to allow IE-specific CD8+ cytotoxic T cells (CTLs)  to now recognize cells 
containing latent virus. 
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